



**THOMSON MEDICAL GROUP LIMITED**  
(Incorporated in the Republic of Singapore)  
(Company Registration No. 199908381D)

---

**S\$25,000,000 4.65% NOTES DUE 2029 BY THOMSON MEDICAL GROUP LIMITED (TO BE CONSOLIDATED AND FORM A SINGLE SERIES WITH THE EXISTING S\$160,000,000 4.65% NOTES DUE 2029 ISSUED ON 29 OCTOBER 2024) TO BE ISSUED PURSUANT TO ITS S\$1,000,000,000 MULTICURRENCY DEBT ISSUANCE PROGRAMME**

---

The Board of Directors of Thomson Medical Group Limited (the “**Issuer**”) wishes to announce that it has launched and priced S\$25,000,000 in aggregate principal amount of 4.65% notes due 2029 (to be consolidated and form a single series with the existing S\$160,000,000 4.65% notes due 2029 issued on 29 October 2024 (the “**Existing Series 005 Notes**”)) (the “**Series 005 Tranche 002 Notes**” and, together with the Existing Series 005 Notes, the “**Series 005 Notes**”). The Series 005 Tranche 002 Notes will be issued by the Issuer pursuant to the S\$1,000,000,000 Multicurrency Debt Issuance Programme established by the Issuer on 28 June 2019 and updated on 21 April 2023 (the “**Programme**”). The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch has been appointed as the sole dealer in relation to the Series 005 Tranche 002 Notes.

The principal terms of the Series 005 Tranche 002 Notes are as follows:

<b>Issue Size:</b>	<b>S\$25,000,000 (to be consolidated and form a single series with the Existing Series 005 Notes)</b>
<b>Issue Price:</b>	<b>100.00% of the principal amount of the Series 005 Tranche 002 Notes (plus accrued interest from and including 29 October 2024 up to but excluding 5 March 2025)</b>
<b>Denomination:</b>	<b>S\$250,000</b>
<b>Issuer’s Redemption Option for Taxation Reasons:</b>	<b>At par, in accordance with the Programme</b>
<b>Issuer’s Redemption Option in the case of Minimum Outstanding Amount:</b>	<b>At par, in accordance with the Programme</b>
<b>Noteholders’ Redemption Option upon cessation or suspension of trading of shares:</b>	<b>At par, in accordance with the Programme</b>
<b>Interest:</b>	<b>4.65% per annum payable semi-annually in arrear</b>
<b>Maturity Date:</b>	<b>5 years from 29 October 2024</b>
<b>Security:</b>	<b>None</b>

**The Series 005 Tranche 002 Notes are expected to be issued on 5 March 2025 (subject to satisfaction of customary closing conditions) and listed on the Singapore Exchange Securities Trading Limited (“SGX-ST”) on the market day after such issue.**

The Series 005 Tranche 002 Notes will constitute direct, unconditional and unsubordinated obligations of the Issuer and shall at all times rank *pari passu*, without any preference or priority among themselves, and at least *pari passu* with all other present and future unsecured obligations (other than subordinated obligations and priorities created by law) of the Issuer.

The Series 005 Tranche 002 Notes are offered by the Issuer in Singapore to institutional investors (as defined in Section 4A of the Securities and Futures Act 2001 of Singapore (the “SFA”)) pursuant to Section 274 of the SFA and accredited investors (as defined in Section 4A of the SFA) pursuant to and in accordance with the conditions specified in Section 275 of the SFA and (where applicable) Regulation 3 of the Securities and Futures (Classes of Investors) Regulations 2018 of Singapore.

The net proceeds arising from the issue of the Series 005 Tranche 002 Notes under the Programme (after deducting issue expenses) will be used for general corporate purposes of the Group, including refinancing of borrowings, financing potential acquisitions, strategic expansions, general working capital, capital expenditure and other investments of the Group.

Application will be made to the SGX-ST for the listing and quotation of the Series 005 Tranche 002 Notes on the SGX-ST. Such permission will be granted when the Series 005 Tranche 002 Notes have been admitted to the Official List of the SGX-ST. The SGX-ST assumes no responsibility for the correctness of any of the statements made, opinions expressed or reports contained herein. Approval in-principle from, admission to the Official List of, and the listing and quotation of the Series 005 Tranche 002 Notes on, the SGX-ST are not to be taken as an indication of the merits of the Issuer, its subsidiaries, its associated companies (if any), the Programme or the Series 005 Tranche 002 Notes.

**By Order of the Board**

**Wilson Sam**

Executive Director and Group Chief Financial Officer

27 February 2025